Pathogens (Jul 2019)

<i>In Vitro</i> Evaluation of Combined Commercialized Ophthalmic Solutions Against <i>Acanthamoeba</i> Strains

  • María Reyes-Batlle,
  • Glorian Mura-Escorche,
  • Ines Sifaoui,
  • Alejandro Otero-Ruiz,
  • Rosalía Alfaro-Sifuentes,
  • Atteneri López-Arencibia,
  • Pedro Rocha-Cabrera,
  • Olfa Chiboub,
  • Aitor Rizo-Liendo,
  • Jonadab Zamora-Herrera,
  • Carlos J. Bethencourt-Estrella,
  • Rubén L. Rodríguez-Expósito,
  • Desirée San Nicolás-Hernández,
  • José E. Piñero,
  • Jacob Lorenzo-Morales

DOI
https://doi.org/10.3390/pathogens8030109
Journal volume & issue
Vol. 8, no. 3
p. 109

Abstract

Read online

Acanthamoeba is a free-living amoebae genus which is present worldwide in natural and artificial environments. These amoebae are clinically important as causative agents of diseases in humans and other animals such as a fatal encephalitis or a sight threatening Acanthamoeba keratitis (AK). Lately; studies have focused on the search of novel therapeutic options for AK but also to prevent infections. Furthermore; the evaluation of commercialized products seems to be an option for this case since not clinical assays would be required. Thus; we aimed to test the amoebicidal activity of different mixtures of two commercial ophthalmic solutions: Systane® Ultra; which has already shown anti-Acanthamoeba properties; and Naviblef® Daily Care. In addition, we tested their cytotoxic effect against murine macrophages. At the individual level; Naviblef® Daily Care showed to be the most active product against Acanthamoeba spp. Nevertheless; the combinations of Systane® Ultra and Naviblef® Daily Care; showed an improvement in the activity against trophozoites and cysts of Acanthamoeba castellanii Neff. Moreover; the concentration necessary to generate cytotoxic effect against murine macrophages (J774.1) was much higher than the required for the amoebicidal and cysticidal effect achieved in the most effective mixtures.

Keywords